1. Home
  2. ENTG vs VTRS Comparison

ENTG vs VTRS Comparison

Compare ENTG & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Entegris Inc.

ENTG

Entegris Inc.

N/A

Current Price

$130.90

Market Cap

22.2B

Sector

Industrials

ML Signal

N/A

Logo Viatris Inc.

VTRS

Viatris Inc.

N/A

Current Price

$16.72

Market Cap

18.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ENTG
VTRS
Founded
1966
1961
Country
United States
United States
Employees
N/A
30000
Industry
Plastic Products
Medicinal Chemicals and Botanical Products
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.2B
18.7B
IPO Year
2000
2019

Fundamental Metrics

Financial Performance
Metric
ENTG
VTRS
Price
$130.90
$16.72
Analyst Decision
Buy
Buy
Analyst Count
10
4
Target Price
$133.67
$13.50
AVG Volume (30 Days)
1.9M
6.7M
Earning Date
04-30-2026
05-07-2026
Dividend Yield
0.27%
3.21%
EPS Growth
N/A
N/A
EPS
1.21
0.05
Revenue
$3,196,600,000.00
$14,299,900,000.00
Revenue This Year
$9.27
$4.41
Revenue Next Year
$9.50
$1.96
P/E Ratio
$107.14
$333.00
Revenue Growth
N/A
N/A
52 Week Low
$67.97
$9.43
52 Week High
$186.94
$18.39

Technical Indicators

Market Signals
Indicator
ENTG
VTRS
Relative Strength Index (RSI) 42.39 50.30
Support Level $125.52 $15.89
Resistance Level $143.07 $17.22
Average True Range (ATR) 4.92 0.41
MACD -0.80 0.00
Stochastic Oscillator 18.09 45.69

Price Performance

Historical Comparison
ENTG
VTRS

About ENTG Entegris Inc.

Entegris is a leading supplier of purification solutions and advanced materials. The vast majority of sales are to the semiconductor industry. The majority of revenue comes from semiconductor fabricators, but the company sells to all areas of the semiconductor manufacturing supply chain including equipment and engineering, chemicals and materials, and distributors. Entegris specializes in materials science and materials purity, both of which are crucial in the semiconductor manufacturing process.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: